3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings
- PMID: 16541247
- PMCID: PMC1705495
- DOI: 10.1007/s00213-006-0322-6
3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings
Abstract
Rationale: 3,4-Methylenedioxymethamphetamine (MDMA) is a widely abused illicit drug. In animals, high-dose administration of MDMA produces deficits in serotonin (5-HT) neurons (e.g., depletion of forebrain 5-HT) that have been interpreted as neurotoxicity. Whether such 5-HT deficits reflect neuronal damage is a matter of ongoing debate.
Objective: The present paper reviews four specific issues related to the hypothesis of MDMA neurotoxicity in rats: (1) the effects of MDMA on monoamine neurons, (2) the use of "interspecies scaling" to adjust MDMA doses across species, (3) the effects of MDMA on established markers of neuronal damage, and (4) functional impairments associated with MDMA-induced 5-HT depletions.
Results: MDMA is a substrate for monoamine transporters, and stimulated release of 5-HT, NE, and DA mediates effects of the drug. MDMA produces neurochemical, endocrine, and behavioral actions in rats and humans at equivalent doses (e.g., 1-2 mg/kg), suggesting that there is no reason to adjust doses between these species. Typical doses of MDMA causing long-term 5-HT depletions in rats (e.g., 10-20 mg/kg) do not reliably increase markers of neurotoxic damage such as cell death, silver staining, or reactive gliosis. MDMA-induced 5-HT depletions are accompanied by a number of functional consequences including reductions in evoked 5-HT release and changes in hormone secretion. Perhaps more importantly, administration of MDMA to rats induces persistent anxiety-like behaviors in the absence of measurable 5-HT deficits.
Conclusions: MDMA-induced 5-HT depletions are not necessarily synonymous with neurotoxic damage. However, doses of MDMA which do not cause long-term 5-HT depletions can have protracted effects on behavior, suggesting even moderate doses of the drug may pose risks.
Figures
Similar articles
-
A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration.Psychopharmacology (Berl). 1999 Nov;147(1):66-72. doi: 10.1007/s002130051143. Psychopharmacology (Berl). 1999. PMID: 10591870
-
MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.Psychopharmacology (Berl). 2007 Jan;189(4):489-503. doi: 10.1007/s00213-005-0174-5. Epub 2005 Oct 12. Psychopharmacology (Berl). 2007. PMID: 16220332
-
Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA).Int Rev Neurobiol. 2009;88:257-96. doi: 10.1016/S0074-7742(09)88010-0. Int Rev Neurobiol. 2009. PMID: 19897081 Free PMC article.
-
The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").Pharmacol Rev. 2003 Sep;55(3):463-508. doi: 10.1124/pr.55.3.3. Epub 2003 Jul 17. Pharmacol Rev. 2003. PMID: 12869661 Review.
-
Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity?Psychopharmacology (Berl). 2007 Jan;189(4):471-82. doi: 10.1007/s00213-006-0320-8. Epub 2006 Mar 23. Psychopharmacology (Berl). 2007. PMID: 16555062 Review.
Cited by
-
Synthetic Cathinones: Epidemiology, Toxicity, Potential for Abuse, and Current Public Health Perspective.Brain Sci. 2024 Mar 29;14(4):334. doi: 10.3390/brainsci14040334. Brain Sci. 2024. PMID: 38671986 Free PMC article. Review.
-
Unlocking the Potential of High-Quality Dopamine Transporter Pharmacological Data: Advancing Robust Machine Learning-Based QSAR Modeling.bioRxiv [Preprint]. 2024 Mar 11:2024.03.06.583803. doi: 10.1101/2024.03.06.583803. bioRxiv. 2024. PMID: 38558976 Free PMC article. Preprint.
-
Dysfunction of the Neurovascular Unit by Psychostimulant Drugs.Int J Mol Sci. 2023 Oct 13;24(20):15154. doi: 10.3390/ijms242015154. Int J Mol Sci. 2023. PMID: 37894832 Free PMC article. Review.
-
Amitriptyline Accelerates SERT Binding Recovery in a Rat 3,4-Methylenedioxymethamphetamine (MDMA) Model: In Vivo 4-[18F]-ADAM PET Imaging.Int J Mol Sci. 2022 Jun 24;23(13):7035. doi: 10.3390/ijms23137035. Int J Mol Sci. 2022. PMID: 35806049 Free PMC article.
-
MDMA for the Treatment of Negative Symptoms in Schizophrenia.J Clin Med. 2022 Jun 7;11(12):3255. doi: 10.3390/jcm11123255. J Clin Med. 2022. PMID: 35743326 Free PMC article. Review.
References
-
- Aghajanian GK, Wang RY, Baraban J. Serotonergic and non-serotonergic neurons of the dorsal raphe: reciprocal changes in firing induced by peripheral nerve stimulation. Brain Res. 1978;153:169–175. - PubMed
-
- Aguirre N, Barrionuevo M, Ramirez MJ, Del Rio J, Lasheras B. Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. Neuroreport. 1999;10:3675–3680. - PubMed
-
- Bai F, Jones DC, Lau SS, Monks TJ. Serotonergic neurotoxicity of 3,4-(+/−)-methylenedioxyamphetamine and 3,4-(+/−)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase. Chem Res Toxicol. 2001;14:863–870. - PubMed
-
- Banken JA. Drug abuse trends among youth in the United States. Ann N Y Acad Sci. 2004;1025:465–471. - PubMed
-
- Bankson MG, Cunningham KA. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin–dopamine interactions. J Pharmacol Exp Ther. 2001;297:846–852. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
